Battle of the Biomarkers: Assessing Key Factors in Prognosis, Monitoring, and Therapeutic Decision-Making for Disease Worsening in Multiple Sclerosis

San Diego, CA US
February 23, 2023

Overview

Over the past several years, the image of multiple sclerosis (MS) has been changing from distinct categories of disease to a complicated spectrum of interwoven pathologies. As this knowledge evolves, so do approaches to prognosticating, monitoring, and responding to disease. With many markers of progression still under investigation and therefore not included in modern guidelines, MS clinicians are left on their own to decide which factors should hold the most weight in influencing clinical decisions. Accordingly, Efficient and Purdue College of Pharmacy Office of Continuing Education (Purdue) are hosting a “debate-based” satellite symposium at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023. During the symposium, MS experts will advocate for their preferred disease indicators and why they are the future of successful MS disease management. In the absence of professional guidelines, these expert perspectives may deepen understanding of exactly how and why these factors should be considered, improving clinicians’ ability to navigate and optimize available tools and strategies for their patients.

Target Audience

This activity is intended for MS specialists, general neurologists, nurse practitioners, physician assistants and other healthcare professionals involved in the diagnosis and long-term management of patients with MS. 

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Assess the relative roles of existing (e.g., lesion topography, disability scales) and emerging (e.g., brain atrophy, cognitive impairment) predictors/indicators of disease progression to guide the prioritization of these factors in proactive assessment of patient changes
  • Appraise the utility of clinical (e.g., timed 25-foot-walk) and radiologic (e.g., magnetic resonance imaging (MRI)) assessments of disease progression to select the most sensitive and clinically appropriate monitoring tools that will not disrupt current workflow
  • Analyze the influence of prognostic factors and clinical indicators on treatment initiation and switching strategies to optimize therapeutic decision-making and maximize patient outcomes
  • Evaluate published research and expert experience with the use of individual DMTs for patients in different disease states (e.g., active/inactive, relapsing/progressive) and with different categories of worsening (e.g., physical vs cognitive) to help determine the optimal therapeutic approach for individual patients
Course summary
Course opens: 
10/13/2022
Course expires: 
02/26/2023
Event starts: 
02/23/2023 - 3:15pm EST
Event ends: 
02/23/2023 - 4:15pm EST
Cost:
$0.00
Rating: 
0

Please check back in mid-November for a detailed Program Outline. The symposium will be organized into the following topics:

Part 1: Weighing Prognostic Indicators in Initial Treatment Selection (20 minutes)

Part 2: Monitoring for Disease Worsening vs Progression (20 minutes)

Part 3: Assessing Treatment Effect and Making Therapeutic Changes (20 minutes)

Marriott Marquis San Diego Marina
333 W Harbor Dr
San Diego, CA 92101
United States

   Robert Shin, MD (Moderator and Chair)
   Director, Georgetown Multiple Sclerosis and Neuroimmunology Center
   Professor, Department of Neurology
   Georgetown University Medical Center
   Washington, DC

 

 

   Jiwon Oh, MD, PhD, FRCPC
   Medical Director, Barlo MS Program
   St. Michael’s Hospital
   Scientist, Keenan Research Centre
   Li Ka Shing Knowledge Institute
   Associate Professor of Medicine
   University of Toronto
   Toronto, Ontario, Canada

 

 

This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC.

 

This independent Industry Supported Satellite Symposium is not included in the ACTRIMS Forum 2023 accredited program.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC and was developed in partnership with the Accelerated Cure Project and Multiple Sclerosis Foundation. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Purdue designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflict of Interest

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

Planners' and Managers' Disclosure

All additional planning committee members, staff and reviewers of Efficient LLC and Purdue University College of Pharmacy have no relationships to disclose.

Faculty Disclosure

Dr. Shin reported the following financial relationships:

  • Consulting Fees: Biogen, Celgene, Genzyme, Novartis
  • Speakers' Bureau: Alexion, EMD Serono, Genentech, Mallinckrodt

Dr. Oh reported the following financial relationships:

  • Consulting Fees: Alexion, Biogen, Bristol Myers Squibb, Novartis, Roche, Sanofi-Genzyme
  • Grants/Research Support: Biogen, EMD Serono, Roche

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

Supported by an educational grant from Novartis Pharmaceuticals Corporation. 

Available Credit

1.00 AMA PRA Category 1 Credit

1.00 Attendance

Price

Cost:
$0.00
Please login or register to take this course.

ACTRIMS Forum 2023 registration is required to attend this independent Industry Supported Satellite Symposium.

Register online at forum.actrims.org.